Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 79

Results For "UP"

7637 News Found

Lupin receives tentative approval from USFDA for DETAF tablets
Drug Approval | February 01, 2023

Lupin receives tentative approval from USFDA for DETAF tablets

DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries


Sun Pharma Q3 FY23 Gross Sales up 13.1%; Net profit up 5.2%
News | February 01, 2023

Sun Pharma Q3 FY23 Gross Sales up 13.1%; Net profit up 5.2%

India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year


Dr. Reddy's Laboratories launches Difluprednate Ophthalmic Emulsion 0.05% in US
News | January 28, 2023

Dr. Reddy's Laboratories launches Difluprednate Ophthalmic Emulsion 0.05% in US

The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA


Dr. Reddys Laboratories Q3 FY2023 consolidated PAT up to Rs. 1243.9 Cr
News | January 27, 2023

Dr. Reddys Laboratories Q3 FY2023 consolidated PAT up to Rs. 1243.9 Cr

The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022


Supriya Lifescience appoints Krishna Raghunathan as CFO
People | January 24, 2023

Supriya Lifescience appoints Krishna Raghunathan as CFO

He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group


US FDA accepts supplemental new drug application for Jardiance for adults with chronic kidney disease
News | January 23, 2023

US FDA accepts supplemental new drug application for Jardiance for adults with chronic kidney disease

The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial


Lupin launches Sacubitril and Valsartan combination drug for heart failure patients
News | January 19, 2023

Lupin launches Sacubitril and Valsartan combination drug for heart failure patients

Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure


Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets
Drug Approval | January 17, 2023

Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets

Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)


1st G20 Health Working Group Meeting to commence on 18th January at Thiruvananthapuram
Policy | January 17, 2023

1st G20 Health Working Group Meeting to commence on 18th January at Thiruvananthapuram

India's G20 Presidency will focus on three main priorities: Health Emergencies Prevention, Preparedness and Response (One Health & AMR); Access and Availability to Affordable Medical Countermeasures (Vaccines, Therapeutics, and Diagnostics); and Digital Health


USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions
Drug Approval | January 17, 2023

USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions

The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22